{"filing":{"accession_number":"0001104659-26-104424","cik":"0001720446","ticker":"ZEPP","company_name":"Zepp Health Corp","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"tm2624658d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720446/000110465926104424/tm2624658d1_6k.htm"},"events":[{"id":31125,"run_id":28549,"accession_number":"0001104659-26-104424","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release announcing Zepp Health's unaudited financial results for the second quarter of 2026, disclosing revenue of US$63.5 million (6.9% YoY growth), gross margin of 37.4%, and net loss of US$11.3 million. The document includes detailed financial and operating highlights, management commentary, balance-sheet metrics, and forward guidance for Q3 2026, all characteristic of a quarterly earnings release. While the exhibit also contains a director resignation and share repurchase update, the primary disclosure is the quarterly financial results announcement.","company_name":"Zepp Health Corp","ticker":"ZEPP","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":33927,"accession_number":"0001104659-26-104424","item_number":"EX-99.1","item_title":"tm2624658d1_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Zepp Health's unaudited financial results for the second quarter of 2026, disclosing revenue of US$63.5 million (6.9% YoY growth), gross margin of 37.4%, and net loss of US$11.3 million. The document includes detailed financial and operating highlights, management commentary, balance-sheet metrics, and forward guidance for Q3 2026, all characteristic of a quarterly earnings release. While the exhibit also contains a director resignation and share repurchase update, the primary disclosure is the quarterly financial results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:09:42.029051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33927,"accession_number":"0001104659-26-104424","item_number":"EX-99.1","item_title":"tm2624658d1_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release announcing Zepp Health's unaudited financial results for the second quarter of 2026, disclosing revenue of US$63.5 million (6.9% YoY growth), gross margin of 37.4%, and net loss of US$11.3 million. The document includes detailed financial and operating highlights, management commentary, balance-sheet metrics, and forward guidance for Q3 2026, all characteristic of a quarterly earnings release. While the exhibit also contains a director resignation and share repurchase update, the primary disclosure is the quarterly financial results announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:09:42.029051+00:00","company_name":"Zepp Health Corp","ticker":"ZEPP","filing_date":"2026-09-02"}]}